A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Clinical trial NCT06315491 · TERMINATED

Trial details

NCT number: NCT06315491
Sponsor: Cybrexa Therapeutics
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Platinum-resistant Ovarian Cancer Refractory Ovarian Carcinoma

Start date: 2024-09-25
Primary completion: 2025-10-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.